Blog

Category: Therapeutics

Paul Stead Joins Adaptimmune as Vice President of Business Development

PHILADELPHIA, Pa. and OXFORD — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead, B. Pharm, PhD, MBA, MR PharmS has joined the Company as Vice President of Business Development.
“I am delighted to welcome Paul to Adaptimmune. Paul has a tremendous wealth of business development experience and joins Adaptimmune at a critical inflection point in the Company’s journey, as we are focused on data delivery from our wholly owned assets,” said Helen Tayton-Martin, Adaptimmune’s Chief Business Officer. “To remain leaders in the TCR T-cell therapy field, we must evaluate a broad range of technology partnerships, and Paul’s extensive experience in business development and competitive intelligence will be a tremendous asset to us.”

“I am thrilled to assume this challenging business development role, building upon my existing experience in pharmaceutical discovery and development,” said Paul. “This is a pivotal year for Adaptimmune, and I am eager to forge partnerships with other industry leaders as we bring TCR T‑cell therapy closer to approval.”

Read More

Cipla Health to expand consumer health biz with new launches and acquisitions

Cipla Health, the consumer healthcare arm of Cipla, plans to revitalize its over-the-counter (OTC) consumer business through more in-house launches and brand acquisitions in the coming quarters.

at switching Cipla’s prescription products into consumer products and organic launches wherever there is a huge unmet need of it like the immune-boosters that we launched now,” said Anantha Nayak, Chief Executive Officer of Cipla Health.

“We are also actively looking at any kind of inorganic growth through mergers and acquisitions,” Nayak added.

He said the company is looking at new product launches in segments such as gastrointestinal, pain and analgesic, cough and cold and nutritional supplements.

Read More

Lacey mental health hospital approved for US HealthVest

A new mental health hospital in Lacey has been given the go-ahead by the Washington state Department of Health.

US HealthVest has been awarded the “certificate of need” for a 75-bed behavioral health center to be placed in an old office building in Lacey’s Woodland District.

Chief Executive Officer Richard A. Kresch, M.D, says the facility will be an in- and out-patient treatment center with an average stay of around seven to eight days.

Kresch says the hospital will specialize in treatment for Detox, psychiatric needs, and behavioral services. He believes the center will be open in late 2018.

Read More

Oviva Health brings in $12M for dietary support platform

Zürich, Switzerland-based Oviva Health, developer of a dietary intervention delivery platform, has secured $12 million in Series A funding. Participants in the round include Albion Capital, Eight Roads Ventures, F-Prime Capital Partners, Partech Ventures, and Walking Ventures.

Oviva was founded in 2014 after observing dietitians’ need for improved patient engagement and is currently active in Switzerland, Germany, and the UK, CEO and cofounder Kai Eberhardt explained. Along with allowing patients to self-record eating habits, weight, and physical activity, the platform’s mobile app allows dietitians to directly communicate with their patients to provide remote diet and nutrition guidance.

Read More

Apellis Pharmaceuticals Announces Closing of its Initial Public Offering

CRESTWOOD, Ky. — Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its initial public offering of 10,714,000 shares of common stock at a public offering price of $14.00 per share. The total gross proceeds to Apellis were approximately $150.0 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares were sold by Apellis. In addition, Apellis granted the underwriters a 30-day option to purchase up to 1,607,100 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The shares commenced trading on the NASDAQ Global Select Market under the ticker symbol “APLS” on Thursday, November 9, 2017.

Citigroup, J.P. Morgan and Evercore ISI acted as joint book-running managers for the offering.

Read More

TraceLink acquires ROC IT Solutions

TraceLink Inc., which specializes in connecting the life sciences supply chain and providing real-time information sharing, has acquired ROC IT Solutions, a leader in intelligent edge data capture for serialized product inventory in the pharmaceutical supply chain.

The acquisition positions TraceLink as the only end-to-end platform that enables life sciences companies to capture, process and exchange serialized product data across a digital supply chain network and also more effectively manage warehouse product inventory at the “edge” of the supply chain.

By acquiring ROC IT and integrating the edge solution, EdgeTRAC, into its family of serialization software solutions, TraceLink now offers solutions for serialized receiving, picking, shipping, returns, deactivation, aggregation, de-aggregation, label printing, and tag management of pharmaceutical products, alongside its serialization software, country compliance solutions, and unique track and trace network currently used by more than 650 global customers to exchange compliance data with more than 255,000 supply chain endpoints.

Read More

PatientPing’s Community Comes to Wisconsin Through Partnership with Bellin Health

BOSTON — PatientPing, a health technology company that connects providers to seamlessly coordinate patient care, announced today it has launched in Wisconsin through its partnership with Bellin Health, an integrated healthcare delivery system based in Green Bay, Wisconsin. This partnership means that providers within Bellin Health can now collaborate on shared patients with other providers outside their network and across the care continuum, enabling a team-based, coordinated approach to patient care.

“At Bellin, quality of care and patient safety are our top priorities. In order to effectively manage the care of our patients, we need to better understand where they access services,” said Dr. Brad Wozney, Bellin Health Medical Director, Ambulatory Quality and Information. “PatientPing will allow us to do just that so we can better coordinate care. We are extremely proud to partner with them on this important initiative.”

Read More

VitalWare™ Once Again Named to Inc. Magazine’s 36th Annual List of America’s Fastest-Growing Private Companies

For a 3rd year in a row, VitalWare™, a leading provider of healthcare revenue cycle SaaS solutions earned a spot on the Inc. Magazine 5000 Annual list of America’s Fastest-Growing Private Companies. VitalWare ranked #1467 on its continued strong three-year growth trend of 277%.

“It’s an incredible honor and validation to be named to the Inc. 5000 list for a 3rd year in a row,” said VitalWare’s CEO and President, Kerry Martin. “VitalWare’s growth and client success is a direct result of our solid client partnerships, innovative solutions, and stellar staff.”

VitalWare is only one of 18 Washington State companies to make the Inc. 5000 list for three consecutive years running, and the only SaaS technology company in the state to make the list from outside the Western Washington High Tech Corridor.

“We are very proud of the unique origins of VitalWare, and employ incredible talent from across the country, and across the healthcare industry to make sure we are continuously applying new thinking, and putting client experience at the center of our product development efforts,” added Martin.

Read More

Artemis Health Secures $16 Million Series B Round to Equip Employers with Actionable Employment Benefits Data

Artemis Health, a company that offers a benefit optimization data platform for employers, received $16 million in Series B funding. The investment was led by F-Prime Capital (the venture capital funds of FMR LLC, the parent company of Fidelity Investments), with participation from previous investors Maverick Ventures and Kickstart Seed Fund. This is the second major round of funding Artemis Health has raised in 12 months, totaling $26 million to date, and will fuel the company’s rapid expansion through investments in thought leadership, product research & development, and key executive hires.
“We believe that everyone should have good healthcare they can afford, and this round of funding greatly enhances our ability to empower employers to make that a reality by leveraging their data,” explained Grant Gordon, CEO of Artemis Health. “As the cost of healthcare soars and healthcare policy remains in flux, the kind of insight the Artemis Platform provides is more critical than ever. We are seeing increasing demand for our benefits optimization platform from companies of all sizes, and these funds will not only allow us to serve our growing client base, but also to add some new and exciting capabilities to our platform.”

 

Read More

Orient Speech Therapy Center Ltd. Collaboration First for China

Australia – In a ground-breaking first for both countries, The University of Newcastle (UON) has partnered with Orient Speech Therapy Center Limited (OST) to develop a world-class speech pathology training program for its clinics in China.

In its early stage of development in China, speech pathology is not offered at a tertiary level, contributing to an inadequate supply of speech pathologists treating serious conditions including autism, swallowing/feeding skills and speech therapy after cleft palate repair.

Recognising the vast and immediate needs of its more than one billion population, OST sought the help of UON’s global speech pathology curriculum expert, Dr Sally Hewat, to create a cutting-edge training programme, helping to produce China’s first cohort of world-class speech pathologists.

OST’s CEO, Edward Yiu said the collaboration was a vital step in advancing China’s burgeoning speech pathology industry. “This is the first time anyone has brought together speech pathology clinical practice and academic rigor to this degree in China so what we are doing is quite ground-breaking. It signals exciting advancements in the standards of speech pathology clinical practice in China, which are crucial to support the rapid growth of this emerging industry.”

Read More